Earendil Labs and WuXi Biologics have jointly signed an agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer and other diseases.

Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development and GMP manufacturing. The collaboration is designed to accelerate regulatory timelines, enhance CMC execution reliability and support scalable global clinical development across Earendil Labs' programmes.

WuXi Biologics has built a strong track record in developing complex biologics, particularly its technology strengths in bispecific and multispecific antibodies and ADCs. By 2025, a total of 945 projects were advancing on the company's integrated CRDMO platform, with bispecific and multispecific antibodies representing one of the fastest-expanding categories.

Jian Peng, PhD, CEO, Earendil Labs, said, "Partnering with WuXi Biologics enables us to advance our pipeline with greater speed, precision and CMC excellence. By integrating Earendil Labs' AI-driven protein-engineering capabilities with WuXi Biologics' deep expertise in complex biologics as well as its proven end-to-end development and manufacturing capabilities, we can more efficiently advance our pipeline towards clinical milestones to deliver meaningful clinical benefit and transform patient treatment."

Leveraging next-generation technology platforms such as the WuXia TrueSite targeted-integration CHO cell line platform and the WuXiHigh high-throughput formulation platform—together with expanded capabilities for high-dose and subcutaneous delivery, including the Hyaluronidase Co-Formulation platform and large-volume device solutions—the company provides development pathways designed to increase efficiency, strengthen product consistency and enable seamless scale-up from early research through commercial manufacturing.

Chris Chen, PhD, CEO, WuXi Biologics, commented, "We are delighted to enter this strategic collaboration with Earendil Labs, a company distinguished by its strong scientific leadership and innovative approach to advancing next-generation immunotherapies. By leveraging our proven expertise across complex biologics—including bispecific and multispecific antibodies as well as ADCs—and our industry-leading technology platforms across drug research, development and manufacturing, we aim to accelerate the advancement of Earendil Labs' innovative pipeline. Through this collaboration, we are poised to accelerate development, ensure robust and scalable manufacturing, and ultimately bring transformative therapies to patients worldwide."